Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab in HER2-amplified biliary tract cancers
NCT04466891Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Oct 2020
- Primary completion
- Jul 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of zanidatamab in biliary tract cancer (BTC), sponsored by Jazz Pharmaceuticals plc. Started Oct 2020; status: completed.
02
Drugs
zanidatamab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04466891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04466891.